Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation

Cayci F. S., Cakar N., Hancer V. S., Uncu N., Acar B., Gur G.

PEDIATRIC NEPHROLOGY, cilt.27, sa.12, ss.2327-2331, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 12
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00467-012-2283-9
  • Dergi Adı: PEDIATRIC NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2327-2331
  • Ankara Üniversitesi Adresli: Hayır

Özet

Background Hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in childhood. It usually occurs after a prodromal episode of diarrhea and it leads to significant morbidity and mortality during the acute phase. However, cases that start as diarrhea-positive HUS whose renal function fail to recover should be screened for genetic disorders of the complement system, which is called atypical HUS (aHUS).